Angle Share Discussion Threads

[kryptonsnake] 29/4/2024 11:40

Did the company tell you what happens after the 6 months?

What about other deals and sales?

You know nothing


LOLsss

[outsizeclothes.com] 29/4/2024 11:39

The 'shareholder/institutional placing' experts ignore one blatantly obvious fact: - there are more ways than 1 of raising cash.
What if some company, like AZ or Essai, took, let's say, a 10%-20% stake in Angle for the necessary money?
What if they managed to get away a high interest bond?

[adw198] 29/4/2024 11:25

Nothing material £££ will come from the AZ deal prior to the cash running out. That’s my view - yours appears to be that we won’t need funding despite the company themselves saying they will.

[gooosed] 29/4/2024 11:20

Bermudashorts - Post Rec your 24086.

[kryptonsnake] 29/4/2024 11:20

Angle release 4 material RNSs this year and Adw198 thinks nothing material will come in the next 12 months


LOLsss



Adw19828 Apr '24 - 22:45 - 24076 of 24089
0 0 3
@nogelpm

*Of* it all works it will hopefully be worth lots $$$ in the medium / long term. Nothing material will land here before Q2 25

[adw198] 29/4/2024 11:06

@&krypton if you don’t think they’ll be a placement that’s fine, all views valid.
I dumped mine this morning, was hoping for the US patent RNS to spike us but definitely want to be out before results. Good luck to those who hold

[kryptonsnake] 29/4/2024 10:55

ohwhatfun

You're using an awful lot of words just to warn us about a placing

Funny how all these experts started showing up after the Astra RNS ??


LOLsss

[kryptonsnake] 29/4/2024 09:17

Adw198 sold his shares and magically became a fortune teller

I might sell my shares if it helps me predict tomorrows lottery numbers


LOLsss

[bagpuss67] 29/4/2024 08:51

Credit to MrK. Cellkeep also seems to be another piece in the jigsaw for AGL and it's aspirations in the Her2 testing market.

[sawney] 29/4/2024 08:50

Bermuda

Thanks for that...

[bermudashorts] 29/4/2024 08:46

sawney

Yes, first and foremost of course AZN's Enhertu update this morning is great news for breast cancer patients. Enhertu is going from strength to strength and has literally transformed the whole HER2 therapy space.

Only about 15% to 20% of breast cancer patients are HER2 positive but over 50% are HER2 low and more still are ultra-low. So it's not hard to see how Enhertu has drawn in a huge number of patients. However, it's not just breast cancer. Only a few weeks ago, Enhertu became the first HER2 therapy ever to receive pan tumour approval from the FDA (accelerated approval). So regardless of tumour type, patients with advanced inoperable HER2 positive tumours who have failed on other therapies can receive Enhertu. The clinical trails leading to this approval included patients with biliary tract, bladder, cervical, endometrial and ovarian, lung and pancreatic tumors.

Of course there has to be a significant knock-on effect on companies involved in HER2 testing . It's not just increased volume, it's agreeing new industry standards for HER2 low and ultra low and from what I have read the dust is still settling.

HER2 status can change over time and now we're looking at changes between 4 different categories (neg, pos, low and ultra-low) so monitoring HER2 status has become more important than ever. A quick look at some of the cancers listed above shows how difficult/impossible it would be to monitor patients via tissue biopsy so the incredible success of Enhertu is a fantastic opportunity for the liquid biopsy sector.

Only time will tell whether Angle can capitalise on that but IMO they are doing all the right things with the development of their own HER2 assay and the collaboration with BioView.

[ohwhatfun] 29/4/2024 08:38

Could do, of course, but what is known to be due? News with material cash up front would of course help reduce the reliance on a raise near term.

It looks to me that you have a number of spike chasers that appear in AGL.

EG 4th Jan news, over 40m volume, over 100% rise, but equally there a large intraday moves, some buying the peak and losing 30-40%, a high of 37p, low 22p close 26p having opened at 33p.

Volumes die down, the mass of short term buyers exit. Typical short term patterns of herd invasions.

AZ news back they came but not in the same numbers, 12m volume, hence less volatility, perhaps expectations of the 100% plus, it didn’t happen.

Time rolls on, £15m cash expected year end indicating a burn of near £1.2 mill per month. So about £10.5m in the bank now.
Forecasts of the cash runway include a forecast of £6.6m revenue this year.

Are they on track?

Either way, cash needed, probably the usual £20m, and they can’t let it drag on. Those engaging in deals with AGL need to know they have the finances to deliver.

Results first will indicate if forecasts are on track. Results will give the information needed to potential backers.
It’s a matter that needs concluding.

In theory results imminent, going by previous report dates (April)

[countbasie1] 29/4/2024 07:42

Oh what funCan't argue with a lot of your analysis but a decent RNS or two will mean raising at a higher share price

[ohwhatfun] 29/4/2024 07:39

Gspanner

The news caught attention, some will have had AGL sat in the background waiting for interest/traction, lurking rather than avid followers.

Check out the share price performance and confusing lack of interest in recent years in their tech.

AZ prompt a look, time to buy? The deeper look shows last raise £20m in 2022 at 80p. Various forecasts of a cash runway, H2 2024 to Q1 25 to into Q2 25. The last business update included, slower than expected.

The small cap market has been decimated, share prices obliterated, a mass of examples of angry investors where large discounts have been in play and share price collapses immediately before fund raises.

Posts of yeah buy now big deal, but sensible, risk averse investors look at the full picture.

AGL appear to have left it later in the day to raise funds than usual, perhaps hoping for a higher share price on the back of news.

The market knows they need money, the market is highly risk averse, so if AGL go to market for funding, the market will drop the share price and discount from there.

If 15p is to be the share price pre fund raise game, then a 10p raise would be generous.

It’s just sober market opinions, unaffected by holding (loss or profits).

Typically those shouting the loudest pumping, are looking for a quick exit, knowing the loitering cash issue will impact the share price.

Chances of avoiding dilution are unknown, it’s a coin flip. How many avoid it is the best guide pretty much all have had major dilution with some failing to attract funding at all.

That’s how some see it, it’s opinions based on the reality of the market. The chance of normal market behaviour on a fund raise for AGL, is high.

[countbasie1] 29/4/2024 07:26

More than intersting

[gspanner] 29/4/2024 07:25

Hmm yes, what AZ need is a best in class way to identify foswnpatients most sensitive to those drugs?

[sawney] 29/4/2024 07:15

I would've thought this mornings RNS from AZN was quite significant....

[gspanner] 29/4/2024 07:10

Well I would like to thank all those posters who selflessly gave up their weekend to warn me about the likely placing and profit warnings.

It is truly inspiring to read your well thought out and altruistic comments… Particularly since you have not been seen on this board before.

This morning I’ll sell all my holdings and buy whatever you suggest.

[nigelpm] 28/4/2024 23:02

Right - you know that for a fact do you? You can tell the future?

[adw198] 28/4/2024 22:45

@nogelpm

*Of* it all works it will hopefully be worth lots $$$ in the medium / long term. Nothing material will land here before Q2 25

[nigelpm] 28/4/2024 22:37

Quite yas. The point indeed is that if AZ like it then we're off and perhaps they can avoid further equity dilution funding.

[adw198] 28/4/2024 22:26

Sensible readers will have seen it exactly as you described. It might lead to more revenues - it might not.


Either way funding is required.

[yasx] 28/4/2024 18:07

Readers need to consider the 150k in the appropriate context - it is not a ‘deal’ or intended to be a one off payment from Angle’s perspective but is viewed as a pathway to much higher revenues in future if utilised by AZ for diagnostic purposes across a plethora of trials.

The same will be the case for other similar transactions.

These forums have many dim contributors, both bulls and bears.